Net loss (USD, thousands)

Depreciation and amortization expense (USD, thousands)

Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan (USD, thousands)

Stock-based compensation - PAVmed Inc. 2014 Equity Plan (USD, thousands)

Change in fair value - Senior Secured Convertible Note (USD, thousands)

Loss on issue - Senior Secured Convertible Note (USD, thousands)

Debt extinguishment loss - Senior Secured Convertible Note (USD, thousands)

APA-RDx: Issue common stock - termination payment (USD, thousands)

Amortization of common stock payment for vendor service agreement (USD, thousands)

Changes in operating assets and liabilities: Accounts receivable (USD, thousands)

Changes in operating assets and liabilities: Prepaid expenses and other current assets (USD, thousands)

Changes in operating assets and liabilities: Accounts payable (USD, thousands)

Changes in operating assets and liabilities: Accrued expenses and other current liabilities (USD, thousands)

Changes in operating assets and liabilities: Due To: PAVmed Inc. - operating expenses, employee related costs, MSA Fee (USD, thousands)

Net cash flows used in operating activities (USD, thousands)

Cash flows from investing activities: Purchase of equipment (USD, thousands)

Cash flows from investing activities: Purchase of intellectual property from PAVmed Inc. (USD, thousands)

Net cash flows used in investing activities (USD, thousands)

Cash flows from financing activities: Proceeds – issue of preferred stock (USD, thousands)

Cash flows from financing activities: Proceeds – issue of common stock - Registered Direct Offering, net of fees (USD, thousands)

Cash flows from financing activities: Proceeds – issue of Senior Secured Convertible Notes (USD, thousands)

Cash flows from financing activities: Payment – repayment of Senior Secured Convertible Note (USD, thousands)

Cash flows from financing activities: Proceeds – issue of common stock – At-The-Market Facility (USD, thousands)

Cash flows from financing activities: Proceeds – exercise of stock options (USD, thousands)

Cash flows from financing activities: Proceeds – issue common stock – Employee Stock Purchase Plan (USD, thousands)

Net cash flows provided by financing activities (USD, thousands)

Net increase (decrease) in cash (USD, thousands)

Cash, beginning of period (USD, thousands)

Cash, end of period (USD, thousands)

a44beb4a7ca54793a81daf1f7ae54e45572438b04d099cb0a984cbcf7286ecb9

Revenue (USD, thousands)

Cost of revenue (USD, thousands)

Sales and marketing (USD, thousands)

General and administrative (USD, thousands)

Amortization of acquired intangible assets (USD, thousands)

Research and development (USD, thousands)

Total operating expenses (USD, thousands)

Operating loss (USD, thousands)

Interest income (USD, thousands)

Interest expense (USD, thousands)

Debt extinguishments loss - Senior Secured Convertible Note (USD, thousands)

Loss on issue and offering costs - Senior Secured Convertible Note (USD, thousands)

Other income (expense), net (USD, thousands)

Loss before provision for income tax (USD, thousands)

Provision for income taxes (USD, thousands)

Net loss attributable to Lucid Diagnostics Inc. (USD, thousands)

Less: Deemed dividend on Series A and Series A-1 Convertible Preferred Stock (USD, thousands)

Less: Series B Convertible Preferred Stock dividends earned (USD, thousands)

Net loss attributable to Lucid Diagnostics Inc. common stockholders (USD, thousands)

Net loss per share attributable to Lucid Diagnostics Inc. common stockholders - basic and diluted (USD)

Weighted average common shares outstanding, basic and diluted (shares)

1cd05e94afc0a219b13346eaa8caf784c43daef9502548682b9973e9c58170bb

Cash (USD, thousands)

Accounts receivable (USD, thousands)

Inventory (USD, thousands)

Prepaid expenses, deposits, and other current assets (USD, thousands)

Total current assets (USD, thousands)

Fixed assets, net (USD, thousands)

Operating lease right-of-use assets (USD, thousands)

Intangible assets, net (USD, thousands)

Other assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued expenses and other current liabilities (USD, thousands)

Operating lease liabilities, current portion (USD, thousands)

Senior Secured Convertible Notes - at fair value (USD, thousands)

Due To: PAVmed Inc. - MSA Fee and operating expenses (USD, thousands)

Total current liabilities (USD, thousands)

Operating lease liabilities, less current portion (USD, thousands)

Total liabilities (USD, thousands)

Commitments and contingencies (USD, thousands)

Preferred stock, $0.001 par value, 20,000,000 shares authorized; Series B and Series B-1 Convertible Preferred Stock (USD, thousands)

Common stock, $0.001 par value (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated deficit (USD, thousands)

Total Stockholders’ Equity (Deficit) (USD, thousands)

Total Liabilities and Stockholders’ Equity (Deficit) (USD, thousands)

71db360b8c63fe398029c89b7a1ee66e232d40c8d24d62dae2b569f045394200

EsoGuard Test Results

Total Revenue

20f0ac0f09fcb73c4a0a5e4a7844cc9c9cc5e6fa33cb2d8d7131b27299cb0c20

Sensitivity for EsoGuard Esophageal DNA Test (percentage)

Negative Predictive Value for EsoGuard Esophageal DNA Test (percentage)

Positive diagnostic yield for BE in ENVET-BE study (fold)

Positive diagnostic yield for BE in ENVET-BE study among ACG screening population (fold)

Number of EsoGuard-positive patients who completed confirmatory EGD in ENVET-BE study (patients)

Planned enrollment for NIH R01 study in non-GERD at-risk population (patients)

cdfc19e516178d01b07abd6ea67ba5ecb5e2789d646a37c21eace9c7100c7aba

Lucid Diagnostics Inc (LUCD)

Financials